Advertisement
Merck
Subscribe to Merck

The Lead

FDA Approves Merck Tablet to Reduce Ragweed Allergies

April 17, 2014 4:41 pm | by The Associated Press | News | Comments

U.S. regulators have again approved a Merck & Co. tablet for gradually reducing seasonal allergies, this time for ragweed pollen. Ragwitek tablets dissolve quickly under the tongue. Patients are to take one daily for a few years, starting three months before ragweed season begins in late summer.

FDA Approves Merck’s Allergy Treatment

April 15, 2014 8:04 am | News | Comments

Merck has announced that FDA has approved GRASTEK ® (Timothy Grass Pollen Allergen Extract)...

Pfizer’s Ian Read Becomes PhRMA Board Chairman; Ken Frazier, George Scangos Assume New Posts

April 14, 2014 8:02 am | News | Comments

Ian C. Read, chairman and CEO of Pfizer, Inc, was elected chairman of the Pharmaceutical...

Studies Find New Drugs Greatly Lower Cholesterol

March 29, 2014 3:31 pm | by Marilynn Marchione - AP Chief Medical Writer - Associated Press | News | Comments

A new class of experimental medicines can dramatically lower cholesterol, raising hopes of a...

View Sample

FREE Email Newsletter

Merck Appoints New CFO

March 27, 2014 8:25 am | News | Comments

Merck has announced the appointment of Robert M. Davis, 47, as executive vice president and chief financial officer, effective April 23, 2014. Davis, who will also oversee corporate strategy and corporate business development, will succeed Peter N. Kellogg, 58.

Merck Licenses NanoBio Technology

March 26, 2014 10:23 am | by Associated Press | News | Comments

NanoBio Corporation today announced a licensing agreement with a subsidiary of Merck & Co., Inc., known as MSD outside the United States and Canada, for the use of its nanoemulsion (NE) adjuvant technology.

NOXAFIL® Injection Approved for Intravenous Use

March 14, 2014 1:54 pm | News | Comments

Merck has announced that the U.S. Food and Drug Administration has approved NOXAFIL® (posaconazole) injection (18 mg/ mL), a new formulation of NOXAFIL for intravenous (IV) use. Merck’s antifungal agent is also marketed as NOXAFIL (100 mg) delayed-release tablets and NOXAFIL (40 mg/mL) oral suspension.

Advertisement

FDA Eases Concern About Certain Diabetes Drugs

February 27, 2014 8:04 am | by MARILYNN MARCHIONE, AP Chief Medical Writer | News | Comments

People who take Januvia, Byetta or certain other widely prescribed medicines for diabetes can breathe a little easier — U.S. and European regulators have found no compelling evidence of a link between these drugs and pancreas problems or pancreatic cancer.

Nuevolution Announces License Agreement with Merck

February 21, 2014 8:05 am | News | Comments

Nuevolution A/S has entered an exclusive license agreement with a subsidiary of Merck & Co., Inc., known as MSD outside the United States and Canada, for small molecule compounds targeting an undisclosed intracellular target for use as leads in Merck’s drug discovery and development. 

EMD Serono Strengthens Leadership With New Appointments

February 13, 2014 9:27 am | News | Comments

EMD Serono, Inc. announced today the recent appointments of Gary Zieziula as the company’s Chief Commercial Officer, Allene Diaz as Senior Vice President of Managed Markets, Lisa Buffington as Vice President of US Communications, Alexander Kuta as Vice President and Head of US Regulatory Affairs, and Michael Ruggiero as Vice President of US Government Affairs and Policy.

Merck and Samsung Bioepis to Develop and Commercialize Insulin Glargine Candidate for Diabetes

February 10, 2014 8:45 am | News | Comments

Merck and Samsung Bioepis Co., Ltd., announced today that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes.

Merck to Pay $100M to Settle NuvaRing Lawsuits

February 7, 2014 4:16 pm | by The Associated Press | News | Comments

Merck said Friday it will pay $100 million to resolve lawsuits stemming from side effects associated with its NuvaRing contraceptive ring. Since 2007 Merck has been facing lawsuits from patients and families of women who suffered problems including heart attacks and strokes and even death using NuvaRing.

Advertisement

Pfizer And Merck To Collaborate On Anti-Cancer Combination Studies

February 5, 2014 9:16 am | News | Comments

Pfizer announced today that it has agreed with Merck to explore the therapeutic potential of Merck’s investigational anti-PD-1 therapy, MK-3475, in combination with two Pfizer oncology assets.          

Merck Fourth Quarter Net Drops 14% on Generic Competition

February 5, 2014 8:55 am | by LINDA A. JOHNSON, AP Business Writer | News | Comments

Merck reported a 14 percent decline in fourth-quarter profit as generic competition continued to cut into sales of one-time blockbuster medicines, and unfavorable currency exchange rates reduced overseas revenue.      

Merck Fourth Quarter Net Drops 14% on Generic Competition

February 5, 2014 8:55 am | by LINDA A. JOHNSON, AP Business Writer | News | Comments

Merck reported a 14 percent decline in fourth-quarter profit as generic competition continued to cut into sales of one-time blockbuster medicines, and unfavorable currency exchange rates reduced overseas revenue.      

Partners in New NIH-Industry Project to Find Meds

February 4, 2014 1:43 pm | by The Associated Press | News | Comments

Ten pharmaceutical companies, seven disease-related foundations, the drug industry's main trade group and two huge federal agencies have joined together in an unusual collaboration to share information and speed up creation and approval of new drugs needed by patients.

Canada Approves Merck's Grass Allergy Immunotherapy

February 3, 2014 4:13 pm | by The Associated Press | News | Comments

WHITEHOUSE STATION, N.J. (AP) — Merck & Co. says it's won its first approval for its new immunotherapy tablet for grass allergies, from regulators in Canada. The drug, called Grastek, gradually reduced allergic reactions to grass pollen, by desensitizing the immune system to the substance triggering the allergic reaction.

Advertisement

Merck Joins Companies Ending Chimpanzee Research

January 30, 2014 3:24 pm | by The Associated Press | News | Comments

Merck & Co. is joining two dozen other pharmaceutical companies and contract laboratories in committing to not use chimpanzees for research.                 

Merck Extends Gains as Analyst Lifts Rating

January 27, 2014 3:42 pm | News | Comments

Shares of Merck extended its recent gains Monday after a Morgan Stanley analyst upgraded the stock, praising the drugmaker's direction and offering a far more optimistic forecast for an experimental cancer drug the company is developing.

Merck Blood Thinner Gets 'Yes' Vote from FDA Panel

January 15, 2014 4:18 pm | by The Associated Press | News | Comments

A panel of federal experts has recommended approval for an experimental blood thinner from Merck despite serious side effects including internal bleeding. The FDA's panel of cardiology experts voted 10-1 Wednesday in favor of approving the pill vorapaxar to help prevent clots in patients with a history of heart attacks.

Merck Recalls All Supply of Combo Cholesterol Drug

January 14, 2014 1:49 pm | by LINDA A. JOHNSON, AP Business Writer | News | Comments

Merck is recalling a combination cholesterol drug, wiping out the entire U.S. stock, due to packaging defects that could reduce effectiveness. Merck says the recall covers all four dose strengths and every batch distributed since Liptruzet was launched last May.

Alnylam Acquires Investigational RNAi Therapeutic Assets from Merck

January 14, 2014 8:23 am | News | Comments

Alnylam Pharmaceuticals has announced today the acquisition of Merck’s wholly owned subsidiary Sirna Therapeutics, Inc., comprising intellectual property and RNAi assets including pre-clinical therapeutic candidates, chemistry, siRNA-conjugate and other delivery technologies.

Merck Rises Ahead of Anticlotting Drug Review

January 14, 2014 8:16 am | News | Comments

Shares of Merck rose Monday on the suggestion that its anticlotting drug vorapaxar might be approved for sale despite concerns about an increased risk of bleeding.              

Merck Launches New Weight Loss Business in the U.S.

December 20, 2013 9:20 am | News | Comments

Merck has announced the launch of a new business focused on providing comprehensive, evidence-based weight management interventions for employers, hospitals, medical groups, health plans and patients.        

Merck and GSK to Evaluate Novel Combination Regimen for Advanced Renal Cell Carcinoma

December 18, 2013 7:58 am | News | Comments

Merck has announced the initiation of a clinical trial to evaluate the combination of the company’s investigational anti-PD-1 immunotherapy, MK-3475, and GlaxoSmithKline’s orally administered kinase inhibitor, pazopanib, in advanced renal cell carcinoma.

Merck KGaA: Allergopharma to Invest €40M in Production Facility

December 12, 2013 11:57 am | News | Comments

The new facility, which is estimated to cost nearly €40 million, will be used, among other things, to expand production to serve new markets such as China. In the two - story building, which will be constructed on the current Allergopharma premises, products for the diagnosis and treatment of type 1 allergies.

Merck Advances Development Program for Investigational Alzheimer’s Disease Therapy

December 10, 2013 8:29 am | News | Comments

Merck has provided an update on the development program for MK-8931, a novel investigational oral β-amyloid precursor protein site-cleaving enzyme (BACE) inhibitor.              

Germany's Merck to Buy Materials Supplier AZ

December 5, 2013 3:05 am | by The Associated Press | News | Comments

Germany's Merck KGaA has announced plans to buy AZ Electronic Materials, which supplies high-tech materials for the electronics industry, for about 1.6 billion pounds ($2.6 billion). Pharmaceutical and high-tech materials company Merck said Thursday that it will offer 403.5 pence ($6.61) in cash.

Forest Labs to Cut 500 Jobs in $500M Restructuring

December 2, 2013 10:24 am | by The Associated Press | News | Comments

Forest Laboratories says it plans to cut about 500 jobs as part of a plan to trim $500 million in costs over the next two years. The company also plans to buy back at least $400 million in company stock and agreed to pay $240 million for the U.S. marketing rights to Saphris.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading